Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Changes in Beneficial Ownership

Atabak Mokari, CFO of Corcept Therapeutics, reports transactions involving common stock, including shares withheld for tax obligations, purchases under a company purchase plan, and vesting of restricted stock awards.

Summary

• Atabak Mokari, the CFO of Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On March 1, 2024, 517 shares were withheld by the issuer to cover tax obligations related to the vesting of restricted stock units at a price of $24.06.
• Also on March 1, 2024, Mokari acquired 554 shares through a purchase plan at $24.06 per share.
• Additionally, Mokari acquired 554 shares underlying unvested restricted stock awards granted under the purchase plan at $0.00.
• Following these transactions, Mokari directly owns 9,536 shares of Corcept Therapeutics common stock.
• These holdings include 1,651 shares underlying unvested restricted stock awards granted on June 1, 2023, 398 shares granted on September 1, 2023, and 508 shares granted on December 1, 2023, all vesting on their one-year anniversary.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The CFO's participation in the company's purchase plan could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates